0001104659-19-037459.txt : 20190625
0001104659-19-037459.hdr.sgml : 20190625
20190625180521
ACCESSION NUMBER: 0001104659-19-037459
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190624
FILED AS OF DATE: 20190625
DATE AS OF CHANGE: 20190625
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Versant Venture Capital VI, L.P.
CENTRAL INDEX KEY: 0001687880
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38944
FILM NUMBER: 19919553
BUSINESS ADDRESS:
STREET 1: ONE SANSOME STREET, SUITE 3630
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
BUSINESS PHONE: (415) 801-8100
MAIL ADDRESS:
STREET 1: ONE SANSOME STREET, SUITE 3630
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akero Therapeutics, Inc.
CENTRAL INDEX KEY: 0001744659
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 170 HARBOR WAY
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-487-6488
MAIL ADDRESS:
STREET 1: 170 HARBOR WAY
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
a4.xml
4
X0306
4
2019-06-24
0
0001744659
Akero Therapeutics, Inc.
AKRO
0001687880
Versant Venture Capital VI, L.P.
C/O AKERO THERAPEUTICS, INC.
170 HARBOR WAY, 3RD FLOOR
SOUTH SAN FRANCISCO
CA
94080
0
0
1
0
Common Stock
2019-06-24
4
C
0
3469759
A
3469759
D
Common Stock
2019-06-24
4
C
0
235099
A
3704858
D
Common Stock
2019-06-24
4
P
0
400000
16
A
4104858
D
Series A Preferred Stock
2019-06-24
4
C
0
10666667
0
D
Common Stock
3469759
0
D
Series B Preferred Stock
2019-06-24
4
C
0
722737
0
D
Common Stock
235099
0
D
Represents the total number of shares of common stock received by Versant Venture Capital VI, L.P. ("Versant VI") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.
All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date.
Represents the total number of shares of common stock received by Versant VI upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.
These shares are owned directly by Versant VI. Versant Ventures VI GP, LP ("Versant GP LP") is the general partner of Versant VI and Versant Ventures VI GP-GP, LLC ("Versant GP LLC") is the general partner of Versant GP LP and the ultimate general partner of Versant VI.
On June 24, 2019, Versant VI purchased 400,000 shares of common stock of the Issuer at a price of $16.00 per share pursuant to an underwritten public offering.
Versant Venture Capital VI, L.P. By: Versant Ventures VI GP, L.P. By: Versant Ventures VI GP-GP, LLC /s/ Robin L. Praeger, Managing Director
2019-06-25